ICU Medical, Inc.

ICU Medical, Inc.

ICUINYSE / NASDAQHealthcareMid cap

$172.52-$3.24 (-1.8%)

Last close · Data as of Nov 20, 2026

Market cap
$3.4B
P/E
4607.1x
EV / EBITDA
14.7x
Revenue
$2.2B
Net margin
0.0%
ROCE
3.1%

+28.4% over the last year

ICU Medical, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+7.1%
3M
-5.5%
6M
+33.4%
1Y
+28.4%
5Y
-30.1%

52-week range

Day change -$3.24 (-1.8%) from $176 to $173 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ICUI, bought on each weekday since 2021.

News & filings

What ICU Medical filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthFree cash flow was more than five times net profit in fiscal 2025.

Concerns (1)

  • Return on equity of 0.0% against a peer median of 16.8%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide.

Read moreShow less

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

Sector
Healthcare
Shares outstanding
24.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$3.4B
P/E
4607.1x
P/B
1.6x
EV / EBITDA
14.7x
EV / Sales
2.0x
P/S
1.5x
52-week high
$187.26
52-week low
$115.45

Profitability

Operating margin
4.9%
Net margin
0.0%
EBITDA margin
13.4%
ROE
0.0%
ROCE
3.1%
ROA
0.0%
Asset turnover
0.55

Growth

Revenue
$2.2B
Revenue growth, 1Y
-6.3%
Revenue CAGR, 3Y
-0.7%
Net profit growth, 1Y
-100.6%
Free cash flow
$82.8M

Solvency

Current ratio
2.39
Debt / Equity
0.63
Debt / Assets
0.33
CFO / Net profit
245.69
Cash / Market cap
9.1%

Where the revenue went

Of every $100 of FY2025 revenue, $0 was left as net income.

ICU Medical, Inc. income statement flow, FY2025
ICU Medical, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$1.4B
RevenueGross profit$822.0M
Gross profitResearch and development$87.5M
Gross profitSelling, general and administrative$625.2M
Gross profitOther operating expenses$0.00
Gross profitOperating income$109.3M
Operating incomePretax income$4.4M
Operating incomeInterest and other expense$105.0M
Pretax incomeTax and other$3.6M
Pretax incomeNet income$730.0k

Revenue and net profit

Revenue fell 6.3% in FY2025; net profit is the dashed line.

ICU Medical, Inc. revenue and net profit by fiscal year
ICU Medical, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$2.3B-$74.3M
FY2023$2.3B-$29.7M
FY2024$2.4B-$117.7M
FY2025$2.2B$732.0k

Cash flows

FY2025: $179.8M from operations, $82.8M free after investment (dashed).

ICU Medical, Inc. operating and free cash flow by fiscal year
ICU Medical, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$62.1M-$161.5M
FY2023$166.2M$72.5M
FY2024$204.0M$113.8M
FY2025$179.8M$82.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$2.2B-6.3%1Y
EBITDA
$298.4M+14.8%1Y
Net profit
$732.0k
Cash from operations
$179.8M-11.9%1Y
Free cash flow
$82.8M-27.2%1Y
Revenue CAGR, 3Y
-0.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$2.2B$298.4M$732.0k$82.8M0.0%-6.3%-100.6%

Monthly returns

Month-by-month returns of ICUI across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$4.1B
Liabilities$1.9B
Equity$2.1B
Paid-in capital$1.5B
Retained earnings$690.9M
Treasury stock$20.0k

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ICUI highlighted.

P/E against peers

ICUI trades at 4607.1x earnings against a peer median of 19.0x (a 24161% premium).

Not shown (no positive earnings and no EV / Sales): Arcus Biosciences, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
ICU Medical, Inc.ICUIthis companyP/E ↑ premium$3.4B4607.1x1.6x0.0%14.7x
Catalyst Pharmaceuticals, Inc.CPRX$3.8B17.9x4.0x22.5%10.6x
Merit Medical Systems, Inc.MMSI$3.8B29.3x2.4x8.1%12.5x
ACADIA Pharmaceuticals Inc.ACAD$3.7B9.5x3.0x31.9%30.8x
Organon & Co.OGN$3.5B18.8x4.7x24.9%9.0x
Concentra Group Holdings Parent, Inc.CON$3.2B19.2x8.1x42.3%12.7x
Integer Holdings CorporationITGR$3.1B30.6x1.8x5.9%15.2x
Arcus Biosciences, Inc.RCUS$3.1B-8.8x4.9x-55.9%-8.9x
National HealthCare CorporationNHC$2.9B24.5x2.7x11.2%13.7x
Peer median—19.0x3.5x16.8%12.6x

Year-to-date ROI

ICUI since 1 January, against earlier years.

Historical volatility

ICUI's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

ICU Medical, Inc. operating margin by fiscal year
ICU Medical, Inc. operating margin by fiscal year
DateOperating margin
FY2022-0.2%
FY20232.1%
FY20244.1%
FY20254.9%
LineFY2025
Cost of revenueCost Of Revenue$1.4B
Gross profitGross Profit$822.0M
Operating expensesOperating Expense$712.7M
Research and developmentResearch And Development$87.5M
Selling, general and administrativeSelling General And Administration$625.2M
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$2.1B
Pretax incomePretax Income$4.4M

Learn while you research

Academy chapters picked for ICU Medical, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 4607.1, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →